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Abstract 
The landscape of the investigation and management of Giant Cell Arteritis (GCA) is 
advancing.  In this review we will outline the recent advances by searching the 
current English literature for relevant articles using key words of Giant Cell Arteritis; 
temporal arteritis; Horton’s disease; investigation; and treatment.  Delay in 
diagnosis, diagnostic uncertainty and glucocorticoid (GC) morbidity are among the 
highest concerns of clinicians and patients in this disease area.  The positive news is 
that fast track pathways, imaging techniques and new therapies are emerging for 
routine management of GCA.  Future directions for intervention in the treatment 
paradigm will be discussed.   
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Introduction 
Giant cell arteritis (GCA) is a granulomatous medium and large-vessel vasculitis1. It is 
the most common form of systemic vasculitis, with an incidence of between 15 to 25 
cases per 100,000 persons over 50 years of age2. The incidence of GCA increases 
with age, almost exclusively affecting people 50 years of age or older3. Women 
account for 65 to 75% of patients; the lifetime risk of GCA in women is 1% compared 
to 0.5% in men3,4. It mainly affects Caucasians and has a higher incidence in 
Scandinavian countries and in populations of northern European descent5. It is rare 
in Asian and Black Caribbean/ African populations6,7. 
 
GCA remains a medical emergency because of the risk of sudden irreversible sight 
loss and stroke. It is a spectrum of phenotypically overlapping conditions including 
cranial GCA, extra-cranial GCA (otherwise termed large vessel GCA, usually involving 
the aorta and its larger supra-aortic branches) and polymyalgia rheumatica 
(PMR)5,8.The most commonly affected cranial arteries are the temporal, ophthalmic, 
posterior ciliary and vertebral arteries9. 22-83% of newly diagnosed GCA patients 
have imaging evidence of large vessel-GCA10. 
 
In clinical practice GCA can be multifaceted: this is due to the seriousness of the 
condition, diagnostic uncertainty and morbidity associated with treatment. Over the 
past decade there has been an increased awareness of GCA, leading to an increase in 
admissions for investigations for suspected GCA11. Thus, improved diagnostic 
pathways, specific tests and targeted management are imperative.  
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Pathophysiology of Giant Cell Arteritis 
GCA mainly affects the medium and large arteries of the external cranial branches of 
the aorta. The pathological process occurring in GCA is summarised below2,3,12,13: 
1. Proceeding from an unknown trigger, there is abnormal maturation of 
vascular dendritic cells (DC) in the adventitia of the large vessel walls. These 
activated DC recruit and activate cluster differentiation (CD) 4+ naïve T cells.  
2. Naïve CD4+ cells are activated and differentiate to T helper (Th) 1 cells, Th17 
and T regulatory (Treg) cells.  
3. Macrophages within the tunica adventitia of the vessel wall produce IL-6 and 
IL-1β. Within the tunica media, macrophages secrete metalloproteinases, 
which degrade the internal elastic lamina and other connective tissue. 
Reactive oxygen species and secreted IL-6 contribute to inflammation, local 
vascular damage. Vascular damage and macrophage-derived growth factors 
such as VEGF and platelet derived growth factor (PDGF) cause intimal 
hyperplasia and subsequent vascular stenosis and occlusion.  
4. In some patients, IFN-γ promotes the differentiation and fusion of highly 
activated macrophages to form multinucleated giant cells. These giant cells 
also secrete cytokines and growth factors.  
5. The injured arterial cells respond to damage through dysfunctional repair. 
This leads to media thickening, luminal occlusion, ischaemia and eventually 
end organ damage. 
 
Genetic influences in GCA 
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A genetic component to the development of GCA is supported by evidence of 
differential prevalence depending on the ethnicity, familial aggregation and multiple 
genetic associations.  GCA has a strong association with the human leukocyte 
antigen (HLA) region, notably the HLA class II genes14, which suggests the role of the 
immune system in its pathophysiology. The number of identified loci remains low, 
and the reasons for this include the fact that GCA is not common within the general 
population making it hard to identify susceptibility signals15. Two independent 
signals have been found within the HLA region that are associated with GCA 
predisposition – one between HLA-DQA1 and HLA-DQA2, and another between HLA-
DRA and HLA-DRB115.  
 
Non-HLA associations have been associated with an increased risk of GCA, namely 
PLG (involved in the plasminogen system) and P4HA2 (collagen synthesis); both of 
these have an important role in neoangiogenesis16. Genes encoding 
proinflammatory cytokines can increase the patient’s risk of ischaemic 
complications, PMR and relapsing disease. The future potential for stratifying the 
disease, and providing targeted therapy has been posulated14.   
 
Role of infection in the development of GCA 
A potential correlation between onset of GCA and infection is postulated: in analyses 
infections are found to be more common in GCA patients than non-GCA prior to 
their diagnosis17,18. This leads to a number of theories regarding infection and GCA: 
namely that infections could be directly responsible for causing GCA from an 
unregulated inflammatory response, or that the pre-existing immune system 
Running title: GCA review for EYE 
 6 
alterations due to the genetic polymorphisms could increase both the risk of 
infection and development of vasculitis. 
 
In support of the theory that infectious agents trigger GCA specific infectious agents 
have been found in temporal artery specimens of those diagnosed with GCA, with 
some then postulating them as a causative factor for the development of GCA.  
These include herpes simplex virus, chlamydia pneumonia, mycoplasma pneumonia, 
Epstein-Barr virus, parvovirus B1919 and varicella zoster virus (VZV)20. However, to 
date no clear conclusions can be drawn, as viruses such as VZV are ubiquitous and 
the data is currently conflicting. 
 
Seasonal and geographic variation in GCA 
Geo-environmental factors have been implicated in the development of GCA and De 
Smit and colleagues, not only investigated seasonal patterns of temporal artery 
biopsies (TAB) from Australia and New Zealand, but also summarised the literature21. 
They found that there was no statistically significant relationship between the 
season of presentation.  On analysis of prior studies, they found results to be 
inconsistent with regard latitude, altitude, solar exposure, socioeconomic status and 
urban versus rural living again with little conclusion21. 
 
Disease Associations  
PMR is considered by some to be a variant of GCA, where overt vasculitis has either 
not commenced or is possibly prevented by an unknown inhibiting mechanism5. 40 
to 60% of patients with GCA also have PMR, conversely 16 to 21% of PMR patients 
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have GCA – perhaps resulting from sharing of genetic risk factors and 
pathogenesis22. GCA should be considered in PMR patients with marked 
constitutional symptoms and / or elevated acute phase reactants and where there is 
an inadequate response to glucocorticoids or relapse23,24. PMR typically presents 
with bilateral shoulder pain and stiffness which is abrupt in onset (usually reaching a 
peak within two weeks) and worse in the mornings25. Other symptoms suggestive of 
PMR include pelvic girdle aching for more than two weeks, morning stiffness for 
more than 45 minutes, functional impairment and constitutional symptoms26. 
However, exclusion of a wide range of imitating conditions is also required (e.g. 
other rheumatological illness such as osteoarthritis or rheumatoid arthritis, drug-
induced, endocrine, infective and neoplastic conditions). 
 
Other associations include a significant increased risk of peripheral arterial disease in 
GCA: the risk ratio among patients with GCA compared with controls was 1.88 (95% 
CI 1.04-3.41)27. Socio-economic deprivation has been reported in GCA, independent 
of classic cardiovascular risk factors 28; some consider this evidence that ischaemic 
complications result predominantly from diagnostic delay 29.  
 
Clinical Presentation – systemic features 
Typical clinical features include new-onset headache, scalp tenderness, jaw 
claudication, fever, fatigue, malaise, anorexia, weight loss and polymyalgia30. In most 
cohorts, new onset headache is typical in about two third of patients, whilst jaw 
claudication is present in under 50%. Jaw claudication is defined as pain and fatigue 
in the masseter muscles on protracted or vigorous chewing which eases with rest. It 
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should not be confused with TMJ dysfunction, dental or gum disease. Tongue 
claudication is less common, however if present, the likelihood of GCA increases5. 
Headache in GCA can be described as an ache, most commonly over the temporal 
arteries, but it can occur anywhere over the head. The region over the temporal 
artery may be sensitive to touch (termed allodynia). Temporal artery abnormalities 
such as beading (irregular contour), prominence, tenderness with an absent pulse 
are reported to increase the likelihood ratio for a positive temporal artery biopsy31 
(Figure 1) , although one third of biopsy proven GCA patients have normal temporal 
arteries on clinical examination. 
 
Constitutional symptoms are present in up to 50% of patients with cranial GCA, 
including fever, fatigue, night sweats, anorexia and weight loss. These features can 
be dominant in 15% of patients at first presentation and 20% of patients when 
relapsing5. The fever associated with GCA is usually low grade, but with the potential 
to reach 39 to 40 degrees centigrade. This is due to a strong systemic acute phase 
response32. Polymyalgic symptoms are the most common extra-cranial 
manifestation. Peripheral musculoskeletal manifestations are reported in GCA and 
PMR, including arthritis, swelling of the distal extremities with pitting oedema (more 
likely PMR than GCA), tenosynovitis and carpal tunnel syndrome33, although their 
presence should alert the clinician to possible alternative diagnoses such as 
rheumatoid arthritis. Due to the wide ranging phenotype, clinicians require a high 
index of suspicion for GCA29 because atypical presentations of GCA may delay 
diagnosis and lead to further complications34. 
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The American College of Rheumatology (ACR) classification criteria were created in 
1990 (Figure 2). The presence of 3 or more of 5 criteria were associated with a 
sensitivity of 93.5% and a specificity of 91.2% for GCA when tested in a selected 
population of patients with vasculitis35. The criteria are often mistakenly used for 
diagnosis, where they function poorly. In the usual clinical setting such as a neuro-
ophthalmology or rheumatology clinic they have low sensitivity and poor positive 
predictive value36,37. They have incorrectly labelled GCA as a “headache disease”24. 
 
Understanding of the wider phenotype of GCA indicates that the ACR 1990 
classification criteria require updating: key clinical features of GCA such as 
constitutional and polymyalgic symptoms, major organ threatening features and 
newer imaging techniques such as ultrasound, CT, MRI and FDGPET should be 
included5.  
 
Other short and long-term complications of GCA include stenosis and large-vessel 
aneurysms, including thoracic and abdominal aortic aneurysm38. Clinically, these can 
present as intermittent limb claudication, back and chest pain. Rarer complications 
include stroke, tongue and scalp necrosis3.  
 
Clinical Presentation – visual features 
Visual symptoms can be temporary or permanent.  Temporary double vision from 
cranial nerve palsy occurs in 6-27%.  Amaurosis fugax, where there is complete black 
out of vision for seconds, is a concerning symptom and if disregarded permanent 
visual loss will occur.  Previous visual loss rates, prior to the use of glucocorticoids, 
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were reported between 30-60%39. Currently, vision loss occurs in up to 20% of 
patients with GCA, most commonly due to arteritic anterior ischaemic optic 
neuropathy, and in less than 5% due to choroidal infarction, central and branch 
retinal artery occlusions or posterior ischaemic optic neuropathy1,40. Whilst these 
symptoms can help prevent further ischaemic damage, fewer patients with loss of 
vision reported preceding symptoms than those without vision loss. Risk factors for 
visual loss in GCA are older age, male gender, hypertension, a positive temporal 
artery biopsy and delayed initiation of glucocorticoid5,41. 
 
Securing a diagnosis 
Making a diagnosis of GCA can be difficult due to the non-specific nature of some of 
the symptoms and a wide range of phenotypes9. Diagnosis can be challenging and 
requires a full history, thorough examination and a combination of investigations.  It 
appears that investigations, along with clinician insight, produces the highest 
sensitivity and specificity42.  
 
Serological Investigations 
Evidence of an acute phase response is shown through raised erythrocyte 
sedimentation rate (ESR) or plasma viscosity (PV), and / or c-reactive protein (CRP)43. 
ESR was originally used in the diagnosis of GCA, but a combination of ESR and CRP is 
being used to give the highest sensitivity and specificity for a diagnosis of GCA. PV is 
not influenced by age, gender, time to analyse and haematocrit, therefore thought 
to be better than ESR if available44. Thrombocytosis, normocytic normochromic 
anaemia, with normal white blood cell count or mild leucocytosis can also be 
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predictive of GCA45. Liver transaminases and alkaline phosphatase are often mildly 
elevated. A combination of tests have been found to be strong predictors of a 
positive diagnosis in those with suspected GCA43. 
  
Diagnostic uncertainty in GCA presenting to ophthalmology has increased due to the 
incorrect assumption of the term “occult GCA”.  Occult GCA is defined in the 
ophthalmology literature as ocular signs without systemic symptoms, but with raised 
inflammatory markers31,46. In a small percentage of patients, inflammatory markers 
may be normal47. Whilst inflammatory markers are usually highly elevated in GCA, 
lower CRP and/or ESR may be more common in those with visual loss. In 136 
patients with biopsy proven GCA from one centre, the ESR and CRP values at 
diagnosis were significantly lower in patients with permanent visual loss48. In 
another multi-centre study of 32 patients with GCA, a low inflammatory response 
and the presence of transient cranial ischemic events (such as amaurosis fugax and 
double vision) indicated a high risk of developing irreversible ischemic 
complications (odds ratio 5, 95% confidence interval 2.05-12.2)49. 
 
Imaging investigations 
Cranial Ultrasound 
Vascular ultrasound (US) is used to identify temporal artery oedema, stenosis and 
occlusion in GCA42. In 10 studies (n=696), the sensitivity has ranged from 55% to 
100% and specificity from 78% to 100%. Typically the ‘halo sign’ is observed, which is 
a non-compressible hypoechoic ring around an arterial lumen that represents an 
oedematous thickening of the arterial wall due to inflammation50(Figure 3). A meta-
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analysis published in 2010 found a sensitivity of 68% and a specificity of 91% for the 
unilateral halo sign. The bilateral halo sign was less sensitive, but had a specificity 
approaching 100%51. Ultrasound of the axillary arteries as well as the temporal 
arteries increases sensitivity of the test42,52. Careful clinical evaluation and 
assessment of the pre-test probability of diagnosis of GCA are still required, because 
the halo sign can rarely be found in other forms of vasculitis53. Further study is also 
needed to better define the confounding effects of atherosclerosis on temporal and 
axillary wall thickness54. Ultrasonography is cheaper than MRI; it is non-invasive, has 
rapid access, and allows longitudinal scanning for disease activity; however it 
requires expertise42. The TABUL study investigated cranial ultrasound(US) versus 
temporal artery biopsy (TAB) and showed the sensitivity of TAB was 39% which was 
inferior to ultrasound 54%; but the specificity of TAB was 100% which was superior 
to US at 81%.  Further analysis showed that when combined with clinical judgement 
at two weeks the sensitivity of  TAB increased to 91% and the sensitivity of US to 
93%, with the specificity of 81% for TAB and 77% for US42. A cost saving of £485 was 
found in favour of US. The sensitivity and specificity of ultrasound in TABUL was 
lower than the most recent meta-analysis of US use in GCA, where pooled sensitivity 
was 77% and specificity 96%55.  
 
Vascular ultrasound is more sensitive to glucocorticoid therapy than TAB. In TABUL, 
US sensitivity was 64% if performed within one day of starting prednisolone and 47% 
if performed between 2 and 7 days42. Approximately half of positive US findings will 
be lost within 7 days of steroid treatment44, although the halo sign may persist for 
months in some patients56. TABUL’s ultrasonographers had less scanning experience 
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than others who have published in this field. Although training and access to US 
remain limitations for this technology, this is no reason not to try to develop local 
expertise25. The EULAR 2018 guidance recommends ultrasound as the first diagnostic 
test given adequate expertise and equipment, and if not available TAB57. 
 
18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) 
18F-FDG-PET is usually combined with low-dose computed tomography (CT) to detect 
inflamed vasculature seen in GCA, and this may have a role in assessing disease 
activity and extent of involvement (Figure 4)1. Although large vessel imaging is 
sensitive to glucocorticoid therapy58, uptake can persist despite treatment and 
absence of clinical symptoms in some patients59. There are no standardised criteria 
for 18F-FDG-PET in large vessel vasculitis but a high proportion of clinicians agree 
with the benefits in GCA and diagnostic accuracy40. It has shown a sensitivity of 77% 
and a specificity of 66%60. Whilst use in extracranial involvement of GCA is beneficial, 
it cannot be used for cranial GCA due to the proximity of the brain. Another 
limitation is in detecting vasculitis of the lower limb due to co-morbid 
atherosclerosis which can result in false positive results61.  
 
Research in other imaging modalities 
Research areas in imaging include super high-resolution magnetic resonance imaging 
(MRI) of the superficial and extracranial arteries, and transdermal optical coherence 
tomography (OCT) of the superficial temporal artery. A contrast-enhanced high-
resolution MRI can demonstrate arterial wall thickening with peri-adventitial and 
mural contrast enhancement1. Neuroimaging is not usually required for patients 
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with a typical presentation of GCA, but some patients may have already undergone 
the investigation previously34. Studies have shown MRI to have a sensitivity of 68% 
to 89% and a specificity of 73% to 97%1. Findings that can typically be seen in GCA 
include non-specific enhancement, enhancement of the optic nerve parenchyma, 
perineural sheath and optic chiasm. However, these findings are not exclusive to 
GCA, as they can suggest general orbital inflammatory disease, infiltrating or 
demyelinating disease. On MRI there can also be T2 hypersensitivity, gadolinium 
enhancement and diffusion weighted imaging restriction, all of which can be seen in 
GCA-related anterior ischemic optic neuropathy or posterior ischaemic optic 
neuropathy34.  
 
Transdermal Optical Coherence Tomography (OCT) has been reported in a series of 
eight patients62; it demonstrated that transdermal OCT identified the superficial 
temporal artery. The advantages over TAB were reported to be similar to US and it is 
quick and easy to use. Currently more research would be required to validate the 
transdermal OCT utility in GCA.  
 
Histopathological confirmation 
A positive TAB gives a definitive diagnosis where a chronic granulomatous 
inflammation centred on internal elastic lamina is seen.  The inflammation can be 
transmural or patchy comprising of mononuclear lymphohistiocytic cells and 
occasionally admixed neutrophils and eosinophils.(Figure 5a). Characteristic multi 
nucleated giant cells (figure 5b) often accompany the inflammatory infiltrates, but 
these are not required for the diagnosis. Fragmentation and reduplication of the 
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elastic laminae is usually present (figure 6, 7b).63 Where timely non-invasive imaging 
is unavailable, an early TAB is recommended in all patients where there is suspicion 
of GCA55,64, as over time glucocorticoids will attenuate the histopathological 
features.  Whilst a positive TAB is specific for GCA, it requires an invasive surgical 
procedure.  Uncommon procedural risks include facial nerve injury, scalp 
ulcer/necrosis, discomfort and surgical wound complications.  Stroke has been 
reported as an extremely rare complication during the surgery in one individual who 
later proved to have an asymptomatic carotid occlusion on the side of the surgery as 
the collateral flow had been passing through the biopsied artery65. There is a 
reported high false negative rate due to segmental involvement29.  Since these skip 
lesions are common, a negative biopsy cannot completely rule out GCA. Deeper 
sections throughout the tissue blocks should be made if initial biopsy slides show 
only normal artery, and clinical history and examination should be revisited. 
 
Another histologic pattern seen in TAB is the healed pattern, which shows no 
inflammation in the arterial wall but can demonstrate discontinuous elastic lamina, 
fibrosis of intima/ media and focal calcification (Figure 7a).  An elastic stain (EHVG) 
highlights significant disruption of the internal elastic lamina with defects extending 
over 30-50% of the circumference of the artery (figure 7b66). Controversy in the 
literature exists around healed arteritis, and this should alert the clinician to re-
examine the history and examination of the patient closely.  Additionally, 
atherosclerosis can be a confounding finding in TAB, as it causes intimal hyperplasia 
and fragmentation of the laminar. Thus, an experienced histopathologist has a 
critical role in helping to guide the clinician. The TABUL study42 suggested significant 
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variation between pathologists in the interpretation of temporal artery biopsy 
histology, so consideration should be made to discuss the pathology if the report 
does not fit the clinical picture.  
 
The British Society for Rheumatology (BSR) recommends that TAB specimens should 
be no less than 1cm and preferably more than 2cm67. Post fixation shrinkage also 
needs to be taken into consideration36.  Bilateral primary TAB is common in North 
America, and increases the yield, but is usually unnecessary68.  
 
The TABUL study found TAB had a 99% specificity and 39% sensitivity42.  The 
sensitivity was much lower than others have reported.   In one large cohort of 
patients with suspected GCA undergoing TAB, the main predictors of a positive 
biopsy were age at biopsy, referral from ophthalmology, jaw claudication/pain, 
visual symptoms and raised ESR9.  In TABUL, TAB sensitivity dropped with 
glucocorticoid therapy reported from 48% to 33% if performed within 3 days 
compared to 7 days42. The wider literature suggests that there is a 5-10% reduction 
in positive TAB rate for each week of glucorticoid treatment44. 
 
The result of any diagnostic test should be interpreted in light of the pre-test 
probability. Pre-test probability is estimated by the treating clinician based on the 
history and examination findings, and all available laboratory results. Various 
algorithms or clinical prediction rules have been proposed to help with this, but 
clinical experience remains essential and is why, where possible, all patients with 
suspected GCA should be referred to a specialist42. 
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Other assessments worth considering in GCA 
Consider performing a screen for infection including dipstick urinalysis and Chest X-
ray (CXR); and a search for mimicking diseases with protein electrophoresis; thyroid 
function tests; and anti-cytoplasmic neutrophil antibodies (ANCA). Baseline CXR, 
echocardiogram or large vessel imaging are advocated by some centres to assess for 
large vessel complications at baseline, in higher risk groups. Occasionally a contrast-
enhanced MRI head and orbits may be indicated examining the anterior visual 
pathways where the cause of an optic neuropathy is not clear. 
 
Determination of pre-existing comorbidities such as hypertension, diabetes mellitus, 
cataract, cardiovascular disease, peptic ulcer disease, osteoporosis, and glaucoma is 
important as the treatment can initiate or worsen disease status (Figure 8).  Noting 
co-medication with non-steroidal anti-inflammatory drugs (NSAIDs) and anti-
coagulants is important both for immediate and long-term care in GCA. 
 
Management of GCA 
GCA is an emergency and many consider that it needs to be treated at the point of a 
suspected diagnosis due to the threat of sight loss.  The principles of management of 
GCA are to protect vision, to limit other end organ damage and minimise 
glucocorticoid toxicity and morbidity.  
 
Fast Track Pathways 
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The mean diagnostic delay for those with cranial symptoms is 9 weeks and 17.6 
weeks for patients presenting without cranial symptoms, due to a combination of 
multiple factors including delayed presentation, delayed clinical suspicion and 
delayed referral for specialist assessment and confirmatory diagnostic tests69. Public 
awareness of GCA is low and primary care doctors are faced with the often non-
specific nature of many early symptoms of GCA and a high prevalence of similar 
symptoms in the general consulting population69. If glucocorticoids are started, but 
specialist referral is delayed, then the potential for a secure diagnosis is reduced, the 
clinical signs may have resolved and the diagnostic tests are less likely to be positive 
with increasing time.   
 
To address these challenges, in certain centres fast-track pathways have been 
established, providing widely advertised, rapid access to specialist clinical 
assessment, diagnostic evaluation including vascular ultrasound or other diagnostic 
tests and immediate therapy. Such pathways have been shown to reduce sight loss 
and have led to significant cost-savings due to reduction of inpatient care42 and 
reduction in TAB rate42,53. In one fast track centre, sight loss was reduced from 37 to 
9% 41, in another from 27 to 8%56. In a third centre, although visual disturbance was 
equal in the historical and fast track groups, risk of permanent blindness reduced by 
88% in the fast track group70. 
 
Immediate Treatment 
Immediate glucocorticoids are the treatment of choice for patients with suspected 
GCA, however there is uncertainty regarding the optimum dose1. Patients who 
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present to the ophthalmology community with cranial ischaemic symptoms and/or 
ophthalmic symptoms are traditionally offered high dose pulse therapy of 
glucocorticoid with 0.5-1.0g methylprednisolone for 3-5 days64,67. This reduces the 
cumulative dose of oral glucocorticoid1, but there is no evidence that this reduces 
rates of sight loss. The current BSR and European League Against Rheumatism 
(EULAR) guidelines suggest immediate treatment of GCA using 1mg/kg 
glucocorticoid (up to a maximum of 60mg/day) or 40-60mg/day equivalent64. This is 
to reduce the risk of ischaemic complications, especially to prevent vision loss64,67. 
For those without cranial ischaemic symptoms, an initial dose of 40mg/day is 
deemed adequate.  
 
Maintenance therapy 
Tapering regimens are empirical. The 
BSR guidance recommends a 
glucocorticoid taper over about 1-2 
years, although this may need to be 
adjusted according to response67.  
 
Observational cohort studies report relapses in 34-62% of patients, requiring an 
increase in glucocorticoid dose, and / or slowing of the tapering regimen24. Patients 
should be warned to expect treatment for about two years, whilst most patients are 
off glucocorticoids at 4-5 years. A small percentage of patients need glucocorticoids 
indefinitely44. Up to 7% of patients experience recurrent vision loss at 3 years29,40. 
Those who are at high risk of more prolonged glucocorticoid therapy or relapse 
Suggested tapering regime by BSR67 
 40-60mg prednisolone until 
symptoms and lab results are 
normal (2-4 weeks) 
 Reduce dose by 10mg every 2 
weeks to 20mg  
 Reduce dose by 2.5mg every 2-4 
weeks to 10mg 
 Reduce dose by 1mg every 1-2 
months if there is no relapse  
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include women, those with peripheral arthritis, high initial inflammatory markers 
and those with evidence of large vessel involvement1,71. Due to the protracted 
glucocorticoid burden, there may be significant adverse effects40.  
 
6% of patients receiving steroid therapy develop serious neuropsychiatric 
complications72. This effect is dose dependent, with the incidence rapidly rising once 
at 40mg/day of steroid73. Other adverse effects include the development of a 
cushingoid appearance, weight gain and skin atrophy. There are also comorbidities 
that can be exacerbated by glucocorticoid therapy, including diabetes, glaucoma and 
osteoporosis1.  
 
Adjunctive therapy in Giant Cell Arteritis 
One of the key areas for development in GCA has been to bridge the unmet need for 
adjunctive therapy.  GCA patients typically exceed a cumulative dose of 5000mg 
prednisolone over several years with up to 85% experiencing glucocorticoid related 
side effects [Proven].  In the UK alone over 33% had a reported cumulative dose over 
10,000mg74: the adverse event hazard ratio rising by 3% for every 1000mg 
increase74.  In addition, those with disease refractory to glucocorticoids (Table 1) and 
those intolerant or with significant adverse effects from glucocorticoids (Figure: bar 
chart of co-morbidities) require adjunctive treatment. 
 
Methotrexate 
Methotrexate has been tested as a steroid-sparing agent and in refractory GCA75-77. 
Currently EULAR recommends considering methotrexate in every patient diagnosed 
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with GCA, whereas BSR recommends treatment for patients with refractory 
disease64,67 based on evidence from three small RCTs75–77. A meta-analysis of these 
trials displays only modest efficacy of 7.5-15mg methotrexate once per week as an 
adjunct in GCA78. Doses of 15-25mg methotrexate weekly, which are conventionally 
used, have not been formally tested in GCA. The most common adverse effects 
include gastrointestinal upset, mouth ulcers, temporary hair loss, elevated liver 
enzymes, leukopenia and teratogenicity1.  
 
Aspirin  
Aspirin is an oral anti-platelet drug, which reduces platelet aggregation, thereby 
inhibiting thrombosis formation29.  It also has a wide range of effects on the immune 
system, inducing tolerance in dendritic cells, inducing Treg and suppressing the 
transcription of IFN-γ79,80. Since glucocorticoids only have marginal effects on IFN-γ, 
aspirin should theoretically complement their effect in GCA29. Due to its 
antithrombotic action, a small case series of GCA patients have supported its use to 
reduce the risk of ischaemic events81. However, there is a lack of adequate evidence 
supporting the use of aspirin in GCA, so the clinician must weigh up the potential 
benefits over potential morbidity29. Adverse effects of aspirin include 
gastrointestinal and cerebral haemorrhage, which will be exacerbated by co-
prescription with glucocorticoid.  
 
Cyclophosphamide   
In a case series of 35 patients with refractory GCA, 90.3% (n=28) responded to 
cyclophosphamide with improved disease activity and sustained reduction in 
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prednisolone dose82. A literature review of GCA patients treated with 
cyclophospahmide83 showed 84% (n=88) were responsive, alongside other 
immunosuppressive agents as part of maintenance therapy. However, the rate of 
side effects was high (33%), and the positive result likely to be affected by reporting 
bias. The lack of prospective or RCT data and the side effects of cyclophosphamide, 
especially in this older group of patients, including life threatening infection, limit its 
use in GCA. 
 
Mycophenolate 
There has been one small case series (n=3) suggesting potential of using 
mycophenolate in GCA84. 
 
Leflunomide 
This inhibits dendritic cell maturation and decreases production of IL-6, TNF, IL-12 
and IL-17.  It has been shown to have efficacy in Takayasu arteritis and  
granulomatosis with polyangiitis85 and is widely used in both psoriatic and 
rheumatoid arthritis. The most common side effects include diarrhoea, raised blood 
pressure, elevated liver enzymes and leukopenia. There are case series highlighting 
its use as a steroid-sparing agent in large vessel vasculitis85,86. Adizei 201286, showed 
22 out of 23 difficult-to-treat GCA patients had either a partial or complete response, 
as well as a reduced cumulative glucocorticoid dose. Diamantopoulos 201385 showed 
good responses with 11 refractory GCA patients.  Recently an open label study 
comparing Leflunomide as adjunctive therapy to standard care and glucocorticoids 
alone found that three quarters of the leflunomide group had reduced relapse rate 
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and decreased cumulative doses of glucocorticoids. Leflunomide needs further high-
level evidence to support its use in GCA87.  
 
Anti-Tumour Necrosis Factor (TNF) Therapy  
TAB specimens show TNF in abundance in patients with GCA88. The exact role of TNF 
in the pathogenesis of GCA is still unclear and the role of anti-TNF therapy has not 
been studied with large sample sizes. Anti-TNF therapies have been considered for 
use in refractory cases of GCA or corticosteroid dependence, but are not routinely 
recommended (Table 1)89.  
 
The new era for GCA: targeted treatment 
Tocilizumab  
Tocilizumab (TCZ) is a recombinant humanised anti-IL-6 receptor antibody. This 
competitively inhibits the binding of IL-6 to the membrane bound and soluble IL-6 
receptors. IL-6 itself stimulates the release of ESR and CRP from hepatocytes, and 
promotes the transition from acute to chronic inflammation. Its overproduction 
contributes to the pathogenesis of GCA90. Using drugs that inhibit IL-6 should 
thereby halt this inflammatory process.  
 
The GiACTA trial91 investigated the efficacy of 162mg subcutaneous TCZ with a 26-
week prednisolone taper, either weekly or every other week. They found that there 
was a significantly higher rate of sustained remission in the TCZ arms than 
prednisolone arms (14% in the 26-week prednisolone taper, 18% in the 52-week 
prednisolone taper 56% in the weekly TCZ arm and 53% in the alternate week TCZ 
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arm). The time to first flare was also significantly longer in the TCZ arms. TCZ 
reduced the cumulative median prednisolone dose by over 40% and perhaps as a 
result, reported serious adverse events were lower in the TCZ arms.  
 
TCZ has been widely used in rheumatoid arthritis for about ten years and a Cochrane 
review (n=3334)92 showed that TCZ was generally well tolerated. However there is a 
statistically significant association with changes in liver enzymes and total 
triglycerides and cholesterol93. Other adverse drug reactions included 
gastrointestinal haemorrhage and perforation, infection, headache and 
hypertension94. There is also a risk of injection site reactions when the drug is 
administered subcutaneously95. The risk of tuberculosis (TB) reactivation, malignancy 
and hepatitis was not found to be significantly elevated93. A past medical history of 
diverticulitis, may be a contraindication for use in GCA, because of the risk of 
perforation, especially if TCZ is to be used in conjunction with NSAIDs, 
glucocorticoids or methotrexate13. However, at the present time, in the absence of 
any other effective and approved glucocorticoid sparing agent in GCA, the risk of 
perforation must be balanced against the risk of ongoing active disease and high 
dose glucocorticoid use. Studies have shown that there are no differences in the 
safety profile of TCZ in regards to sex, age, concurrent treatment with NSAIDs, 
methotrexate and glucocorticoids or mild renal impairment96. The safety of TCZ in 
patients with moderate to severe renal impairment, hepatic impairment or in 
pregnancy have not yet been studied. Currently, there is a phase 3 clinical trial 
(ClinicalTrials.gov Identifier: NCT03202368) investigating the long-term safety of 
subcutaneous TCZ in patients with GCA who have flare or persisting disease activity. 
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The National Institute for Health and Care Excellence (NICE) and NHS England have 
approved TCZ for restricted use in GCA97.  However, it is currently limited to 
refractory and relapsing disease (Table 1), in those who have not received TCZ 
previously, and for a maximum of one calendar year of treatment.  In the GiACTA 
trial40, 17% of the overall cohort were diagnosed with refractory GCA. Within the 
cohort with refractory GCA, there was a higher prevalence of depression (16% versus 
4%), and osteopenia/osteoporosis (33% versus 23%) compared to those without 
refractory GCA.  
 
Anti-IL-1 Therapy  
Ly et al98 reported the efficacy of Anakinra in 3 patients with refractory GCA, in 
comparison to conventional treatments. The GiAnT trial (ClinicalTrials.gov Identifier: 
NCT02902731) is currently in phase 3 looking at 70 patients who will be randomised 
to two arms: prednisolone plus placebo or prednisolone and 100mg/day anakinra by 
subcutaneous injection. The study is expected to be completed by March 2022.  
 
Anti-T Cell Therapy 
Langford et al, 201799 (n=49), supported the use of abatacept as it showed a 
significantly higher rate of relapse-free survival to standard glucocorticoid therapy 
and it was not associated with a higher rate of toxicity. A clinical trial 
(ClinicalTrial.gov Identifier: 00556439) is currently underway looking at abatacept for 
treating adults with GCA and Takayasu’s arteritis.  
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Conclusion 
GCA remains a disease that causes concern for clinicians and patients either in 
diagnosis or in suspected relapse. Wider access and validation of imaging 
techniques, not only for diagnosis but longitudinal monitoring, is underway.  We are 
now embarking on the era of targeted treatment for GCA, with many avenues to 
pursue.  Patients will benefit from fast track pathways where close partnership with 
other teams that care for those with GCA including rheumatology, medicine, 
neurology and primary care, will facilitate early diagnosis and improve long term 
management. 
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Figure Legends 
Figure 1: Prominent, beaded, pulseless, tender temporal artery in a patient with 
biopsy proven giant cell arteritis. Abnormality detected by patient three weeks prior 
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to new onset temporary, then permanent double vision, followed by anterior 
ischaemic optic neuropathy and complete loss of vision to perception of light. 
Figure 2: Diagram of frequency of symptoms of GCA and the American College of 
Rheumatology (ACR) 1990 criteria for the definite diagnosis of GCA30,100,101. 
Figure 3: These are Temporal Artery Ultrasound images showing (A) longitudinal and 
(B) cross sectional images of a normal artery; (C) longitudinal and (D) cross section 
image of the non-compressible, hypoechoic “halo sign” (white asterisks). 
Figure 4: A 67 year old Caucasian lady presented with headache, PMR, drenching 
night sweats, weight loss and CRP 120. 18FDG PET-CT fused images show18FDG avid 
large vessel GCA (white arrows) of the thoracic aorta in sagittal (A), coronal (B) and 
transverse view (C). Inflammatory activity extends into the subclavian and common 
carotid arteries (D). 
Figure 5: Key histopathological features of GCA.  (A) H&E x 100, superficial temporal 
artery with marked intimal thickening.  (B) Thick arrow head denotes inflammatory 
cells in the media and adventitia.   
Figure 6: Key histopathological feature of GCA with EHVG stain x 200 thick arrow 
head points to fragments of internal elastic laminae remaining and duplication.   
Figure 7: Key histopathological feature of healed arteritis. (A) thick arrow head 
shows calcification at the intima media border and (B) an elastic stain (EHVG) 
highlights significant disruption of the internal elastic lamina with defects extending 
over 30-50% of the circumference of the artery.   
Figure 8: Common co-morbidities and adverse effects of glucocorticoids as adapted 
from Tuckwell et al.  
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Tables 
Table 1: Current definitions of disease state, as adapted from Dasgupta et al, 
2018106 
Terminology Definition 
Relapse Recurrence of signs or symptoms of GCA attributable to GCA as 
determined by the clinician and necessitating an increase in 
treatment in a GCA patient who has previously responded to 
treatment. 
Refractory Those who never achieve remission, regardless of treatment with 
a course of glucocorticoids, which would be considered adequate 
to induce remission. Lower dose regimens may constitute optimal 
care if the maximum safe dose of glucocorticoid must be exceeded 
in order to control disease e.g. in glucocorticoid induced 
psychiatric disturbance, pancreatitis, or uncontrolled diabetes or 
hypertension. 
Remission Absence of signs or symptoms of GCA. 
Sustained 
remission 
Sustained absence of signs or symptoms of GCA. 
 
Table 2: Therapies not routinely recommended for GCA. 
 
Drug Efficacy in GCA 
Azathioprine In a double-blind study of 31 patients with PMR and GCA, 
azathioprine 100-150mg/day appeared to reduce the overall 
cumulative dose of glucocorticoid. However, there was a higher 
discontinuation rate compared to placebo, most likely due to less 
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tolerable adverse effects and so this trial cannot be 
interpreted102.  
Cyclosporine  Cyclosporine A showed no clinical efficacy and carried the risk of 
hypertension and creatinine increment103. 
Dapsone Dapsone showed a moderate efficacy. Its side effect profile 
inhibits routine use with increasing the risk of anaemia, 
agranulocytosis and a rash104. 
Sirukumab This is an IL- inhibitor. The SIRRESTA study (ClinicalTrials.gov 
Identifier: NCT02531633) was designed to evaluate the efficacy 
and safety of this drug in GCA, however it was terminated due to 
a change of rights and its discontinued development in GCA. 
Infliximab Infliximab was reported to be ineffective in Hoffman et al, 
2007105 (n=44) as it failed to improve the rate of remission or 
reduce glucocorticoid requirement. 25% developed antibodies 
against Infliximab 20 weeks after administration of the last dose.  
Adalimumab The HECTHOR trial89 (n=70) reported that 10-week’s treatment 
with adalimumab was not associated with a lower rate of relapse 
or a glucocorticoid-sparing effect.  
Etanercept Martínez-Taboada et al, 200888 (n=17) etanercept was reported 
to have a lower number of relapses, although not statistically 
significant, and a significantly lower overall cumulative 
prednisolone dose. They could not draw definitive conclusions 
due to the small study sample.  
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Summary points: 
What was known before 
1. TAB was the “gold standard” for diagnosis of GCA. 
2. Serum IL-6 was found to be elevated in those with active GCA. 
3. The only effective treatment was with high dose glucocorticoids, which have 
a significant cumulative morbidity in this population. 
What is known now 
1. Tests including non-invasive imaging in conjunction with clinical expertise are 
the current gold standard for diagnosis of GCA.  
2. Fast track pathways reduce GCA related morbidity, such as visual loss; reduce 
the potential for over treatment in those with suspected in GCA and are cost 
effective. 
3. Tocilizumab, an IL-6 inhibitor, is licenced for treatment of all GCA patients.  In 
Scotland, Wales and Northern Ireland it is funded for all GCA patients.  In 
England it funded for refractory GCA for up to one year of treatment. 
 
